Smitherman, PhD Relationship category: Research grants Name of commercial interest: Merck Relationship level: Modest level relationship – (less than $10,000) Deborah E. Tepper, MD Please refer to the disclosure for Stewart J. Tepper (as Atezolizumab spouse) Stewart J. Tepper, MD Relationship category: Consulting fees/Honoraria Name of commercial interest: Allergan, ATI, Impax, Merck, Nautilus, NuPathe, Pfizer,

Zogenix Relationship level: Significant level relationship – (more than $10,000) Relationship category: Speaker’s Bureau Name of commercial interest: Allergan, Impax, MAP, Nautilus, Zogenix Relationship level: Significant level relationship – (more than $10,000) Relationship category: Equity interests/Stock options Name of commercial interest: ATI Relationship level: Modest level relationship – (less than $10,000) Relationship category:

Royalty income Name of commercial interest: University of Mississippi Press, Peoples Publishing House of Peking, Springer Relationship level: Modest level relationship – (less than $10,000) Gretchen E. Tietjen, MD No conflicts of interest Marcelo M. Valença, MD, PhD No conflicts of interest Shuu-Jiun Wang, MD Relationship category: Consulting fees/Honoraria Name of commercial interest: Allergan, Eli Lilly (Taiwan), Pfizer Relationship level: Modest level relationship – (less than $10,000) Relationship category: Speaker’s Bureau Name of commercial interest: Allergan,

Boehringer Ingelheim (Taiwan), Eli Lilly (Taiwan), GSK (Taiwan), Pfizer (Taiwan) Relationship Selleck Tanespimycin level: Modest level relationship – (less than $10,000) Randall E. Weeks, PhD Relationship category: Consulting fees/Honoraria Name of commercial interest: Allergan Relationship level: Modest level relationship – (less than $10,000) “
“Chronic migraine is a common primary headache disorder that actively afflicts as many as 1 in 50 individuals and accounts for a disproportionate share of the financial cost, pain, and emotional suffering produced by migraine generally. Sulfite dehydrogenase “Chronic migraine” implies that one has an established history of migraine, has been experiencing headaches on at least 15 days of each month for at least 3 consecutive months, and the majority of those headaches each month either have had features characteristic of migraine or have been responsive to drugs which are relatively specific for migraine (examples: sumatriptan, rizatriptan, dihydroergotamine). In October 2010 the Federal Drug Administration (FDA) approved onabotulinumtoxinA (onabotA; also commonly referred to as Botox, BotoxA, and botulinumtoxin-type A) injection therapy for the preventive treatment of chronic migraine; this established onabotA as the first (and only) therapy FDA-approved specifically for that indication.